To amend title XI of the Public Health Service Act to reauthorize the program providing for sickle cell disease and other heritable blood disorders research, surveillance, prevention, and treatment.
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023
This bill reauthorizes through FY2028 the Sickle Cell Disease Treatment Demonstration Program, which supports efforts to improve treatment and prevention of sickle cell disease and complications from that disease. (Sickle cell disease is an inherited blood disorder that can lead to pain, anemia, infections, and stroke.)
Introduced in House
Introduced in House
Referred to the House Committee on Energy and Commerce.
Referred to the Subcommittee on Health.
Forwarded by Subcommittee to Full Committee (Amended) by the Yeas and Nays: 28 - 0.
Subcommittee Consideration and Mark-up Session Held
Committee Consideration and Mark-up Session Held.
Ordered to be Reported (Amended) by the Yeas and Nays: 50 - 0.
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 118-166.
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 118-166.
Placed on the Union Calendar, Calendar No. 132.
Mr. Bucshon moved to suspend the rules and pass the bill, as amended.
checking server…
Ask anything about this bill. The AI reads the full text to answer.
Enter to send · Shift+Enter for new line
Considered under suspension of the rules. (consideration: CR H5578-5580)
DEBATE - The House proceeded with forty minutes of debate on H.R. 3884.
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5578)
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5578)
Motion to reconsider laid on the table Agreed to without objection.
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.